^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Triple Negative Breast Cancer
    Drug:Nubeqa (darolutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study on Androgen Receptor and Triple Negative Breast Cancer

    Excerpt:
    ...Androgen receptor (AR)-positive, as defined centrally by a ≥ 10% tumor stained cells by IHC...
    Trial ID:
    UCBG3-06 START
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    6271 / 6 - Hormone receptor inhibition as a strategy for radiosensitization of breast cancer

    Published date:
    05/15/2020
    Excerpt:
    AR inhibition with enzalutamide, apalutamide, and darolutamide showed limited single agent growth inhibition efficacy in AR+ TNBC and AR+, ER+ breast cancer cell lines (IC50 > 10 μM).